Subscribe to RSS
Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinicsFinancial support: The VERITY registry is funded by sanofi-aventis.
14 June 2009
Accepted after major revision: 26 October 2009
22 November 2017 (online)
Venous thromboembolism (VTE) is a clinically important complication for both hospitalised and ambulatory cancer patients. In the current study, the frequency, demographics and risk (according to tumour site) of VTE were examined among patients seen at outpatient DVT (deep-vein thrombosis) clinics. Of 10,015 VTE cases, 1,361 were diagnosed with cancer, for an overall rate of cancer-associated VTE of 13.6% in this outpatient population. Patients with cancer-associated VTE were significantly older than cancer-free VTE cases (66.4 ± 12.7 vs. 58.8 ± 18.5 years; p<0.0001). The frequency of cancer-associated VTE peaked earlier among females than males, occurring in the sixth (137/639, 21.4% vs. 98/851, 11.3%; p<0.001) and seventh decades (213/980, 21.7% vs. 197/1096, 18%; p=0.036). VTE was described most frequently in common cancers – breast, prostate, colorectal and lung (56.1% of cases). The risk of VTE varied widely across 17 cancer types. Calculating odds ratios (OR) to assess the effect size of cancer type on VTE risk, the highest odds were observed for patients with pancreatic cancer (OR 9.65, 95% confidence interval [CI] (5.51–16.91). Tumours of the head and neck had higher odds than previously reported (OR 8.24, 95% CI 5.06–13.42). Reduced risk estimates were observed for skin cancers (melanoma and non-melanoma: OR 0.89, 95% CI 0.42–1.87; OR 0.74, 95% CI, 0.32–1.69, respectively). We conclude that outpatients have a similar rate of cancer-associated VTE as VTE patient populations previously reported, that cancer-associated VTE occurs in an older age group and earlier in females and that outpatients exhibit distinct tumour site-specific risk from that described among hospitalised cancer patients.
* Current position: Medical Manager, Pfizer, Walton-On-The-Hill, Surrey, UK.
- 1 Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003; 29: 247-258.
- 2 Khorana AA, Francis CW, Culakova E. et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-2346.
- 3 Kakkar AK, Haas SK, Wolf H. et al. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost 2005; 94: 867-871.
- 4 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. New Engl J Med 2000; 343: 1846-1850.
- 5 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634.
- 6 Bergqvist D, Agnelli G, Cohen AT. et al ENOXACAN II Investigators.. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
- 7 Haas SK, Kakkar AK, Kemkes-Mathes B. et al. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer-results of the TOPIC studies. J Thromb Haemost. 2005 3: Abstract OR059.
- 8 Verso M, Agnelli G, Bertoglio S. et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a doubleblind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-4062.
- 9 Geerts WH, Bergqvist D, Pineo GF. et al.; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 381S-453S.
- 10 Lyman GH, Khorana AA, Falanga A. et al.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
- 11 O’Shaughnessy D, Rose P, Scriven N. et al. Venous thromboembolism registry: a route to improved patient outcomes. Hosp Med 2004; 65: 260-261.
- 12 Arya R, Paneesha S, McManus A. et al. More on thromboprophylaxis: quantifying risk for venous thromboembolism. Thromb Haemost 2009; 101: 791-794.
- 13 Ageno W, Grimwood R, Limbiati S. et al. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica 2005; 90: 220-224.
- 14 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
- 15 Blom JW, Doggen CJ, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-722.
- 16 Imberti D, Agnelli G, Ageno W. et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008; 93: 273-278.
- 17 Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2004; 128: 291-302.
- 18 Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
- 19 Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87: 1076-1077.
- 20 Khorana AA, Kuderer NM, Culakova E. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
- 21 White RH, Chew H, Wun T. Targeting patients for anticoagulant prophylaxis trials in patients with cancer: who is at highest risk?. Thromb Res 2007; 120 (Suppl. 02) S29-S40.